Repurposing doxepin as an antitumor agent: Suppression of cell migration, invasion and survival in non‑small cell lung cancer through ERK/NF‑κB downregulation
Oncology Letters · 20.11.2026 · 33 (1) · 1-10
DOI: 10.3892/ol.2026.15960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 20.11.2026. Verfasst von Chiung-Yu Chen und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Non‑small cell lung cancer (NSCLC) remains a global health challenge due to high metastatic potential and resistance to conventional apoptosis. Doxepin, a tricyclic antidepressant, has shown emerging antitumor potential, yet its efficacy and underlying mechanisms in NSCLC remain poorly understood. The effects of doxepin were evaluated on NSCLC cell lines (A549 and CL1‑5‑F4). Cell viability and apoptosis were assessed using an MTT assay and annexin V/PI flow cytometry. Migratory and invasive capacities were measured using Transwell assays. Western blotting was employed to investigate the ERK/NF‑κB signaling axis and associated regulatory proteins. Doxepin notably suppressed cell viability and induced apoptosis through both extrinsic (caspase‑8) and intrinsic (caspase‑9) pathways in a dose‑ and time‑dependent manner. Furthermore, doxepin treatment markedly inhibited cell migration and invasion. Mechanistically, doxepin inactivated the ERK/NF‑κB axis, leading to the downregulation of anti‑apoptotic (cellular FLICE‑like inhibitory protein, myeloid cell leukemia 1 and X‑linked inhibitor of apoptosis protein) and pro‑metastatic (vascular endothelial growth factor A and matrix metalloproteinase‑9) factors. These findings demonstrate that doxepin effectively inhibits NSCLC progression by promoting apoptosis and suppressing metastasis, suggesting its potential as a repositioned therapeutic agent for lung cancer treatment.
Zitieren
APA
Chen, C., Chang, S., Dong, D., Hsu, F., Fang, Y., & Lai, J. (2026). Repurposing doxepin as an antitumor agent: Suppression of cell migration, invasion and survival in non‑small cell lung cancer through ERK/NF‑κB downregulation. Oncology Letters, 33(1), 1-10. https://doi.org/10.3892/ol.2026.15960
Vancouver
Chen C, Chang S, Dong D, Hsu F, Fang Y, Lai J. Repurposing doxepin as an antitumor agent: Suppression of cell migration, invasion and survival in non‑small cell lung cancer through ERK/NF‑κB downregulation. Oncology Letters. 2026;33(1):1-10. doi:10.3892/ol.2026.15960
BibTeX
@article{Chen2026,
author = {Chen, Chiung-Yu and Chang, Shih-Chieh and Dong, Dai-Cheng and Hsu, Fei-Ting and Fang, Yi-Jen and Lai, Jiun-I},
title = {Repurposing doxepin as an antitumor agent: Suppression of cell migration, invasion and survival in non‑small cell lung cancer through ERK/NF‑κB downregulation},
journal = {Oncology Letters},
year = {2026},
volume = {33},
number = {1},
pages = {1--10},
doi = {10.3892/ol.2026.15960}
}
EUVIMED